Latest Tumor markers Stories
Men who participate in biennial PSA based screening have a lower risk of being diagnosed as well as dying from prostate cancer up to 9 years after their last PSA test.
A genetic score based on PCa risk-associated single nucleotide polymorphisms (SNPs) is an independent predictor of prostate biopsy outcomes, suggest the results of a new study conducted by a group from the Department of Urology Huashan Hospital, Fudan University in Shanghai, China.
A 23andMe study of consumers' reactions to genetic testing found that even when the tests revealed high-risk mutations in individuals, those individuals had few negative reactions to the news.
Scientists from the University of California, San Francisco (UCSF) recently conducted a study that showed a significantly earlier onset of menopause for women who inherited a mutation in one of the breast cancer susceptibility gene (BRCA) genes.
New market research report “Tumor Markers: Innovative Technologies and Emerging Business Opportunities” worked out by Venture Planning Group (VPG) has been recently published by Market Publishers
- totally perplexed and mixed up.